OR WAIT null SECS
The agency announces that 81 medicines overall were recommended in 2016.
The European Medicines Agency (EMA) recommended seven new medicines for marketing authorization at its December 2016 meeting, bringing the total on recommendations to 81 for 2016. The new drugs target forms of arthritis, lung cancer, non-Hodgkin’s lymphoma, hemophilia, and epilepsy, among other conditions.
EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting market authorization for the following:
CHMP also recommended extending indications for Ameluz, Cinryze, Ilaris, Jardiance, Jentadueto, Keytruda, Tivacy, Trajenta and Votubia.